An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy

Summary The best effective dose of a chemotherapy is defined using the maximum tolerated dose (MTD) of toxicity. It is possible that the toxicity of a dose may increase when the dose-response curve is not monotonic. In the case of metronomic chemotherapy (MC) a 1/10th level of MC dose is considered as a targeted dose of therapy and is safer in terms of toxicity levels. The objective of this study is to develop an algorithm based on the dose response model of MC to evaluate the best effective dose based on the molecular target agent. The molecular target agent is defined as the optimal biological dose achieved by the best effective dose, as the lowest dose with the highest rate of safety and efficacy. The first proposed design is parametric and assumes a logistic dose-efficacy curve for dose determination, and the second design uses quadratic regression to identify the optimal biological dose. We conducted extensive simulation studies to investigate the operating characteristics of the proposed designs. Simulation studies provide a possible way to decide on the best effective dose of MC to be considered in further phases through the finding of the optimal biological dose. The proposed design is assumed, with the threshold value of optimum biological dose (OBD), to detect the best dose of MC. This consistent design with specific dose response models can be recommended for practice.

[1]  L. Saltz Progress in cancer care: the hope, the hype, and the gap between reality and perception. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Fusenig,et al.  Tumour angiogenesis : basic mechanisms and cancer therapy , 2008 .

[3]  Georgia Salanti,et al.  Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. , 2007, The Lancet. Oncology.

[4]  A. Bhattacharjee,et al.  Time-Dependent Area Under the ROC Curve for Optimum Biological Dose Detection Optimum Biyolojik Doz Tespiti için ROC Eğrisi Altinda Zamana Bağli Alan , 2016 .

[5]  Pan Pantziarka,et al.  Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai , 2016, Ecancermedicalscience.

[6]  Y K Cheung,et al.  Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.

[7]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[8]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[9]  D. Ribatti,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 2016 .

[10]  O. Scharovsky,et al.  Metronomic chemotherapy: changing the paradigm that more is better , 2009, Current oncology.

[11]  R. Maiti Metronomic chemotherapy , 2014, Journal of pharmacology & pharmacotherapeutics.

[12]  L. Goldstein,et al.  Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial , 2006 .

[13]  D. Ribatti,et al.  Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 1999 .

[14]  R. Kerbel,et al.  Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Bhattacharjee Multiple Imputations for Determining an Optimum Biological Dose of a Metronomic Chemotherapy , 2017 .

[16]  J. Denekamp,et al.  Endothelial proliferation in tumours and normal tissues: continuous labelling studies. , 1984, British Journal of Cancer.

[17]  U. Dafni,et al.  Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer , 2009, Clinical Cancer Research.

[18]  S. Arya,et al.  A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. , 2015, Oral oncology.

[19]  H. H. Lloyd,et al.  Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. , 1970, Cancer chemotherapy reports.

[20]  C. Marquette,et al.  Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer , 2014, British Journal of Cancer.

[21]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[22]  Alternative of clinical end point selection for metronomic studies , 2017 .